Clinical Efficacy of Composite Autologous Chylated Fat and Concentrated Growth Factors for Treating Postinjection Alopecia After Facial Fillers: A Single-Center Retrospective Study
Tang S., Zhou G., Fu Q., Chen M.
Retrospective Study on Hair Loss, Hair Regeneration, published in J Cosmet Dermatol (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- J Cosmet Dermatol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40501302
- PMCID
- PMC12159710
- DOI
- 10.1111/jocd.70269
- Citations
- 1
Abstract (original English)
Background Postinjection alopecia is a rare but significant complication of facial fillers, likely caused by compromised microcirculation and follicular damage. Effective treatments are needed, but regenerative therapies specifically for this etiology lack systematic investigation. Objective This study evaluated the efficacy and safety of combined autologous chylated fat (ACF) and concentrated growth factors (CGF) for treating acute alopecia following facial filler injection. Methods In this single-center, retrospective case series, nine female patients with acute alopecia (2-4 weeks post-HA filler) were treated between June 2021 and June 2024. Treatment involved three monthly subcutaneous injections of a 1:1 ACF and liquid CGF mixture (0.1 mL/cm 2 ). Outcomes were assessed at 6 months posttreatment initiation, including hair density, diameter, terminal/vellus ratio, anagen/telogen ratio, Global Aesthetic Improvement Scale (GAIS), and adverse events. Results All nine patients completed the 6-month follow-up. Significant improvements (p 2 , hair diameter from 52.3 ± 15.2 to 75.8 ± 21.7 μm, terminal/vellus ratio from 0.31 ± 0.11 to 1.27 ± 0.35, and anagen proportion from 18.4% ± 6.5% to 63.7% ± 14.9%. GAIS scores indicated high satisfaction. Treatment was well-tolerated, with only one patient reporting transient erythema. Conclusion Combined ACF and CGF represent a promising and
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Systematic Review with a reported sample of 724 on Hair Loss, Hair Regeneration, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 724
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
DKK3-CKAP4 signaling drives fibroimmune remodeling and hair follicle miniaturization in androgenetic alopecia
Meta-analysis on Hair Loss, Hair Regeneration, published in Theranostics (2026) — summary generated from the PubMed abstract.
- 2026
Theranostics - Level AMeta-analysisEurope PMC
Systematic review and meta-analysis of the use of micrografting technology in humans
Meta-analysis with a reported sample of 24 on Chronic Wound, Burns, Hair Loss, published in J Int Med Res (2025) — summary generated from the PubMed abstract.
- 2025
- n = 24
J Int Med Res1 citations - Level ASystematic ReviewEurope PMC
Therapeutic potential of stem cell-derived exosomes in hair regeneration: A systematic review
Systematic Review on Hair Loss, Hair Regeneration, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells2 citations - Level ASystematic ReviewPubMed
Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources.
Systematic Review on Hair Loss, Hair Regeneration, published in Clin Cosmet Investig Dermatol (2025) — summary generated from the PubMed abstract.
- 2025
Clin Cosmet Investig Dermatol6 citations